Optogenetic technologies in translational cancer research
- 9 June 2022
- journal article
- review article
- Published by Elsevier in Biotechnology Advances
- Vol. 60, 108005
Abstract
No abstract availableKeywords
Funding Information
- Suzhou University of Science and Technology
- Syöpäsäätiö
- I.M. Sechenov First Moscow State Medical University (GTH-RND-2011, GTH-RND-2112)
- National Institutes of Health (61-5956, GM122567)
This publication has 144 references indexed in Scilit:
- Construction of an Oncolytic Herpes Simplex Virus That Precisely Targets Hepatocellular Carcinoma CellsMolecular Therapy, 2012
- The evolution of heart gene delivery vectorsThe Journal of Gene Medicine, 2011
- New Rabies Virus Variants for Monitoring and Manipulating Activity and Gene Expression in Defined Neural CircuitsNeuron, 2011
- Targeting Tumor Vasculature With an Oncolytic VirusMolecular Therapy, 2011
- Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic VirotherapyMolecular Therapy, 2011
- Rapid blue-light–mediated induction of protein interactions in living cellsNature Methods, 2010
- Engineered Newcastle Disease Virus as an Improved Oncolytic Agent Against Hepatocellular CarcinomaMolecular Therapy, 2010
- High-performance genetically targetable optical neural silencing by light-driven proton pumpsNature, 2010
- Spatiotemporal control of cell signalling using a light-switchable protein interactionNature, 2009
- Hypoxia Enhances the Replication of Oncolytic Herpes Simplex VirusMolecular Therapy, 2009